---
title: "Health Care Up on Rotation Into Lagging Sectors — Health Care Roundup"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286822335.md"
description: "Health-care companies saw gains as traders shifted focus to underperforming sectors. However, Regeneron Pharmaceuticals experienced a significant drop in shares following a failed late-stage study of its fianlimab drug for melanoma. Additionally, an American contracted Ebola in the Democratic Republic of Congo amid an ongoing outbreak."
datetime: "2026-05-18T21:34:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286822335.md)
  - [en](https://longbridge.com/en/news/286822335.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286822335.md)
---

# Health Care Up on Rotation Into Lagging Sectors — Health Care Roundup

Health-care companies rose as traders rotated into some lagging sectors.

Regeneron Pharmaceuticals shares fell sharply in premarket trading Monday after the biotechnology company reported a late-stage study failure of its fianlimab drug candidate in the skin cancer melanoma.

An American contracted Ebola while working in the Democratic Republic of Congo, where the outbreak of the fatal virus is spreading.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

May 18, 2026 17:26 ET (21:26 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)

## Related News & Research

- [Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.](https://longbridge.com/en/news/286811938.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Regeneron's Phase 3 Melanoma Trial Shows Numeric PFS Benefit But Misses Statistical Significance](https://longbridge.com/en/news/286662524.md)
- [Regeneron’s trial fails to reach statistical significance for primary endpoint](https://longbridge.com/en/news/286848216.md)
- [Regeneron Announces Strategic Collaboration With Parabilis Medicines To Advance Novel Antibody-Helicon Conjugates Across Multiple Therapeutic Areas](https://longbridge.com/en/news/286759146.md)